ArticleThe Journal of infectious diseases2025
Real-world Effectiveness of the Adjuvanted Recombinant Zoster Vaccine in ≥50-year-old Adults With Autoimmune Diseases.
Article in The Journal of infectious diseases, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Brief report: Effectiveness and safety of recombinant zoster vaccine in inflammatory bowel disease patients aged 18 years and older: A matched cohort and self-controlled case series study.Human vaccines & immunotherapeutics · 2026Article
- Vaccination Against Herpes Zoster in Adults: Current Strategies in European Union Countries.Vaccines · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
backgroundReal-world data on the vaccine effectiveness (VE) of the adjuvanted recombinant zoster vaccine (RZV) to prevent herpes zoster (HZ) among individuals with autoimmune diseases (AIDs) are limited. To address this knowledge gap, we aimed to evaluate the VE of 2 RZV doses against HZ in ≥50-year-old adults with selected AIDs (rheumatoid arthritis, inflammatory bowel disease, systemic lupus erythematosus, multiple sclerosis (MS), psoriasis (PsO), and psoriatic arthritis).
methodsWe conducted a retrospective matched cohort study using Optum's deidentified Clinformatics® Data Mart Database datasets from January 2018 to December 2021. Patients were matched by AID condition, age, and medication category, then 1:3 by propensity scores that accounted for the likelihood of receiving RZV, adjusted on selected confounders. For each AID, we calculated HZ incidence rates and RZV VE, overall and stratified by age, sex, time interval between 2 RZV doses, medication category, and time since vaccination.
resultsThe 2-dose cohort included 36 645 RZV-vaccinated and 109 229 unvaccinated patients. Two RZV doses offer protection against HZ in patients with AIDs, with VEs ranging from 48.1% for MS to 77.2% for PsO. An overall reduction in HZ incidence from 12.9 (95% confidence interval [CI]: 12.3; 13.5) to 4.3 (95% CI: 3.8; 4.9) per 1000 person-years among vaccinated individuals was found, corresponding to an overall VE against HZ of 66.3% (95% CI: 61.4; 70.7).
conclusionsOur analysis shows that RZV vaccination prevents HZ in ≥50-year-old adults with selected AIDs, consistent with prior studies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.